Objectives: Providing effective enteral nutrition is important during critical illness. In health, glucose is absorbed from the small intestine via sodium-dependent glucose transporter-1 and glucose transporter-2, which may both be regulated by intestinal sweet taste receptors. We evaluated the effect of critical illness on glucose absorption and expression of intestinal sodium-dependent glucose transporter-1, glucose transporter-2, and sweet taste receptors in humans and mice. Design: Prospective observational study in humans and mice. Setting: ICU and university-affiliated research laboratory. Subjects: Human subjects were 12 critically ill patients and 12 healthy controls. In the laboratory 16-week-old mice were studied. Interventions: Human subjects underwent endoscopy. Glucose (30 g) and 3-O-methylglucose (3 g), used to estimate glucose absorption, were infused intraduodenally over 30 minutes. Duodenal mucosa was biopsied before and after infusion. Mice were randomized to cecal ligation and puncture to model critical illness (n = 16) or sham laparotomy (control) (n = 8). At day 5, mice received glucose (100 mg) and 3-O-methylglucose (10 mg) infused intraduodenally prior to mucosal tissue collection. Measurements and Main Results: Quantitative polymerase chain reaction was performed to measure absolute (human) and relative levels of sodium-dependent glucose transporter-1, glucose transporter-2, and taste receptor type 1 member 2 (T1R2) transcripts. Blood samples were assayed for 3-O-methylglucose to estimate glucose absorption. Glucose absorption was three-
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Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (http://journals.lww.com/ccmjournal). fold lower in critically ill humans than in controls (p = 0.002) and reduced by a similar proportion in cecal ligation and puncture mice (p = 0.004). In critically ill patients, duodenal levels of sodiumdependent glucose transporter-1, glucose transporter-2, and T1R2 transcript were reduced 49% (p < 0.001), 50% (p = 0.009), and 85% (p = 0.007), whereas in the jejunum of cecal ligation and puncture mice sodium-dependent glucose transporter-1, glucose transporter-2, and T1R2 transcripts were reduced by 55% (p < 0.001), 50% (p = 0.002), and 69% (p = 0.004). Conclusions: Critical illness is characterized by markedly diminished glucose absorption, associated with reduced intestinal expression of glucose transporters (sodium-dependent glucose transporter-1 and glucose transporter-2) and sweet taste receptor transcripts. These changes are paralleled in cecal ligation and puncture mice. (Crit Care Med 2014; 42:57-65) Key Words: blood glucose; enteral nutrition; glucose absorption; intensive care; small intestine T he importance of enteral nutrition during critical illness is well recognized (1) . However, the provision of adequate nutrition via this route is frequently compromised because absorption is impaired (2) . This can result in the presence of undigested nutrient in the large intestine, which increases the risk of diarrhea, gas formation, and consequent abdominal distension, all of which occur frequently in the critically ill, and may have adverse effects (3) .
The Effects of Critical
The effect of critical illness on carbohydrate absorption is of particular interest given carbohydrate is the predominant macronutrient in standard enteral formulae and is an important determinant of glycemia (4, 5) . 3-O-methylglucose (3-OMG) is a glucose analog that is absorbed via the same transporters but is not metabolized (6) . Measuring postprandial serum concentrations of 3-OMG provides an estimate of glucose absorption in animals, healthy humans, and the critically ill (4, (7) (8) (9) . In health, glucose is primarily absorbed from the intestinal lumen to the enterocyte via the sodium-dependent glucose transporter-1 (SGLT-1), which is located in the brush border membrane, and potentially, via the facilitative glucose transporter-2 (GLUT2), which may relocate to the apical membrane (4) .
Studies in animals have established that intestinal levels of SGLT-1 and GLUT2 transcript and protein are increased in the presence of a broad array of sweet ligands, via an intestinal sweet taste receptor (STR) pathway (10) (11) (12) (13) . The lingual detection of sugars and sweeteners is dependent on activation of a G-protein-coupled STR, a heterodimer of taste receptor type 1 member 2 (T1R2) and taste receptor type 1 member 3 (T1R3) subunits (T1R2/R3) (14) . Sweet taste molecules are also present in the proximal small intestine of humans, and transcript levels, which are likely to reflect subsequent protein levels, are responsive to systemic factors such as glycemia (15) . If intestinal STR mechanisms function in humans as in animals, it is likely that these receptors link the presence of luminal glucose to the increased expression and availability of SGLT-1 and GLUT2 for glucose transport (10-12).
Hyperglycemia occurs frequently in the critically ill, is usually unrelated to antecedent diabetes, and affects outcomes adversely (16, 17) . While the pathophysiology of this hyperglycemia is poorly defined, inadequate insulin and excessive glucagon secretion relative to blood glucose concentrations are considered key contributing factors (16, 17) . In health, the gastrointestinal tract is the principal determinant of insulin secretion in response to ingested glucose, via the release of the "incretin" hormones, glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) (13) . GLP-1 is present in intestinal L-cells, which express STRs, and these have been linked functionally to secretion of GLP-1 in both animals and humans (13, 14, 18) . Accordingly, if critical illness is associated with a reduction in intestinal STR levels, this is likely to impact adversely on the secretion of GLP-1 and, thereby, glycemic control.
The use of an animal model of illness facilitates the study of novel therapies. Cecal ligation and puncture (CLP) mice are a well-described model of severe sepsis (19) . CLP mice can be studied in the "recovery" phase of their illness, which is comparable to the period in which clinicians would like to optimize nutritional therapy in the critically ill.
The primary objective of this study was to determine whether intestinal transcript levels of SGLT-1, GLUT2, and STR (T1R2) are reduced in human critical illness. Secondary objectives were to evaluate the effect of critical illness on glucose-induced secretion of GLP-1, GIP, insulin, and glucagon in humans and to establish an animal model that replicates the molecular and functional intestinal abnormalities observed in critically ill humans.
MATERIALS AND METHODS

Critically Ill Patients and Healthy Volunteers
Mechanically ventilated critically ill patients who were suitable to receive enteral nutrition via a small intestinal feeding catheter were studied between September 2010 and August 2011. Patients were excluded if they were aged less than 18 years, pregnant, known to have diabetes, had a contraindication to endoscopy, had a history of surgery on the stomach, duodenum, or small intestine, were receiving drugs known to alter platelet aggregation or thrombus formation, had an international normalized ratio greater than 1.5, or had a platelet count less than 50 × 10 9 /L. Healthy volunteers were matched as closely as possible to the critically ill subjects for age, sex, and body mass index and the same exclusion criteria applied.
Protocol
Patients were studied after a fast of at least 8 hours. If insulin was being administered, infusions were ceased at least 2 hours before the study. Healthy subjects ingested a liquid nutrient meal the night before the study to replicate recent exposure to enteral feeding in the critically ill (20) . Subjects were studied approximately at the same time of day (09:00 hr) with blood sampled from an IV cannula in health and an existing intra-arterial cannula in patients. A small diameter (5.3 mm) video endoscope was inserted via the nose or mouth into the second part of the duodenum using minimal insufflation of air (15) . Three mucosal biopsies were collected and stored in RNAlater (Qiagen, Doncaster, Victoria, Australia) and the endoscope was left in situ. From 0 to 30 minutes (T0-T30), liquid nutrient (30 g glucose + 3 g 3-OMG [Sigma-Aldrich, Castle Hill, New South Wales, Australia] dissolved in water to a total volume of 150 mL) was infused directly into the duodenum over 30 minutes (i.e., 4 kcal/min). At T30, three further duodenal biopsies were taken, after which the endoscope was removed. Blood was sampled at T0, T10, T20, and T30 for blood glucose and 3-OMG concentrations.
Mouse Model of Critical Illness-CLP
Twenty-seven 16-week-old male C57 mice were randomized to CLP or sham laparotomy (control) groups. The CLP model has been previously detailed by other investigators (19) . In the sham group, the cecum was located, but neither ligated nor punctured. Mice received intensive support for 5 days following surgery with twice-daily fluid resuscitation (1 mL subcutaneous saline) and Terramycin (Pfizer, West Ryde, New South Wales, Australia; 1 mg/100 g body weight) and Butorphanol (Pfizer, 0.5 g/100 g) for the first 2 days. Mice were monitored twice daily for survival and standardized clinical disease scores, which were summed for the entire experiment (cumulative disease index) (21) . On day 5, all surviving mice (n = 24) were fasted for 2 hours then anesthetized with isoflurane (Ceva Delvet, Seven Hill, New South Wales, Australia), a laparotomy performed, and the proximal duodenum cannulated. A warmed liquid nutrient (100 mg glucose bolus + 10 mg of 3-OMG in 1 mL of water) was infused into the proximal duodenum over 30 minutes. Mice were humanely killed by pentobarbitone (Troy Laboratories, Smithfield, New South Wales, Australia) overdose, with blood from terminal bleeds collected for assessment of 3-OMG concentrations. Small intestinal samples were collected into RNAlater (Qiagen) for molecular assays.
Data Analysis
Quantification of Gene Expression by Real-Time RT-PCR. RNA was extracted from human and mouse tissues using RNeasy Mini or Micro kits (Qiagen) following manufacturer's instructions, with RNA yield and quality determined by NanoDrop (NanoDrop Technologies, Wilmington, DE). Quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR) was used to determine absolute levels of T1R2, SGLT-1, and GLUT2 transcript in 25 ng of total human RNA, and transcript levels relative to β-actin in mice. Primers for these targets were used as validated primer assays (QuantiTect, Qiagen; Supplementary Table 1, Supplemental Digital Content 1, http://links.lww.com/ CCM/A706) or in the case of absolute PCR standards, designed from target sequences obtained from the National Center for Biotechnology Information nucleotide database (Supplementary Table 2 , Supplemental Digital Content 1, http://links.lww. com/CCM/A706) (15) . Minimum detectable levels for human SGLT-1 and T1R2 transcripts were 2 × 10 3 copies; when levels were not detected, this threshold value was substituted.
RT-PCR was performed on a Chromo4 (MJ Research, Waltham, MA) real-time instrument attached to a PTC-200
Peltierthermal cycler (MJ Research) using a QuantiTect SYBR Green one-step RT-PCR kit (Qiagen) according to the manufacturer's specifications. Cycling conditions were reverse transcription at 50ºC for 30 minutes, 95ºC for 15 minutes, then 45 cycles PCR at 94ºC for 15 seconds, followed by 55ºC for 30 seconds and 72ºC for 30 seconds. A melt curve was generated (60-95ºC) to verify the specificity and identity of the RT-PCR products; product size was confirmed on an electrophoresis gel (Bio-Rad Laboratories, Hercules, CA). Each assay was performed in triplicate and included internal no-template and no-RT controls.
Blood Glucose, Hormone, and 3-OMG Assays. Blood glucose was measured at the bedside using a portable glucometer (Medisense Optimum, Abbott Park, IL). Both serum and plasma were separated by centrifugation (3,200 rpm for 15 min at 4°C). Samples were then stored at -70°C until assayed. Serum concentrations of 3-OMG were measured in both humans and mice using liquid chromatography/mass spectroscopy with an assay sensitivity of 0.0103 mmol/L (8). Serum insulin was measured in humans by enzyme-linked immunosorbent assay (ELISA) (Mercodia, Uppsala, Uppsala County, Sweden) with sensitivity 1.0 mU/L and coefficient of variation 3.1% within and 5.9% between assays.
Blood samples for glycated hemoglobin (HbA1c), glucagon, and incretin hormones were collected into chilled 5-mL EDTA tubes. HbA1c was measured using cation exchange high-performance liquid chromatography. Plasma glucagon was measured by radioimmunoassay (Millipore, Billerica, MA); the minimum detectable limit was 20 pg/mL and intraand interassay coefficients of variation were 8.5% and 22.5%, respectively. Total GLP-1 was measured by ELISA (Epitope Diagnostics, San Diego, CA) with sensitivity 0.05 pmol/L and intra-and interassay coefficients of variation 5.4% and 3.9%. Plasma GIP was measured by radioimmunoassay (22) . The minimum detectable limit was 2 pmol/L, with intra-and interassay coefficients of variation 3.2% and 9.3%, respectively.
Immunohistochemistry. Fixed tissues were cryoprotected (30% sucrose in phosphate-buffered saline), embedded in cryomolds then frozen. Frozen tissues were sectioned at 6-10 μm (Cryocut 1800, Leica Biosystems, Wetzlar, Germany) and thaw-mounted onto gelatin-coated slides. Immunoreactivity in human tissues was detected using a rabbit T1R2 primary (H90, 1:400, SC-50305, Santa Cruz Biotechnology, Dallas, TX), a monoclonal GLUT2 (1:800, AB85715, Abcam, Cambridge, UK), GIP primary (1:800, AB30679, Abcam), goat SGLT-1 (1:400, SC-47398, Santa Cruz Biotechnology), and GLP-1 primary antibodies (C-17, 1:400, SC-7782, Santa Cruz Biotechnology). All were visualized using species-specific secondary antibodies conjugated to Alexa Fluor dyes (1:200 in phosphate buffered saline + 0.2% Triton X-100 [Sigma-Aldrich]) according to earlier methods (15, 23) . Antigen retrieval (S1700, Dako, Glostrup, Denmark) was performed for T1R2 and SGLT-1 according to manufacturer's instructions. Committee of the Institute of Medical and Veterinary Science, respectively. Informed consent for each patient was obtained from the next of kin and volunteers gave written consent.
Statistical Analysis
The primary endpoints were intestinal transcript copy numbers or relative expression of SGLT-1, T1R2, and GLUT2. The sample size was based on our previous data comparing duodenal RNA levels in ambulant patients with type 2 diabetes, healthy volunteers, or mice (15, 23) . Twelve subjects and a minimum of eight mice per group gave 80% power to detect a difference in RNA expression between groups of 30%, accepting an α error of 0.05. Mice were randomized 2:1 into CLP and sham groups based on best practice mortality of 50% in this model (24); a higher survival rate was achieved in this study, allowing additional CLP mice to reach study endpoints. Data are reported as median (range). Areas under the curves (AUC 0-30 ) were calculated using the trapezoidal rule. Mann-Whitney tests were used to determine differences between patient and healthy groups, and CLP and control mice. Wilcoxon signed rank tests were used to determine significance within group variables. Linear relationships were evaluated using Spearman rank test. Statistical analyses were performed using SPSS (version 17.0; Chicago, IL). All p values are two sided.
RESULTS
Study in Critically Ill Patients
Twelve patients and 12 healthy subjects were studied; none had an abnormal macroscopic appearance of the small intestinal mucosa. The two groups were well matched ( Table 1) .
Duodenal Transcript Levels. SGLT-1 was the most abundant transcript in the duodenum of healthy subjects, with 30% lower levels of GLUT2 (p < 0.001) and much lower levels of T1R2 (p < 0.001) (Fig.1A) .
Fasting levels of SGLT-1 transcript were 49% lower in critically ill patients compared to healthy subjects (p < 0.001) ( Fig. 2A) while fasting levels of GLUT2 were 50% lower (p = 0.009) (Fig. 2B) . T1R2 transcript levels were 85% lower in fasted critically ill patients (p = 0.007) (Fig. 2C ) and were undetectable in four patients at baseline and one patient after glucose infusion. Acute glucose infusion did not significantly alter transcript levels of SGLT-1, GLUT2, or T1R2 in either patients or healthy subjects (i.e., T0 and T30 levels were similar; p > 0.10 for patients and healthy subjects).
Glucose Absorption and Glycemia. Fasting and postinfusion blood glucose concentrations were similar in critically ill patients and healthy controls (at T0: critically ill: 6.0 (Fig. 3A) .
Insulin and Glucagon. Fasting insulin concentrations were similar in patients and healthy subjects (p = 0.55), whereas after glucose infusion, concentrations tended to be lower in the critically ill (p = 0.052), so that the magnitude of increase in insulin was less in the critically ill (p = 0.017) ( Table 2) . Glucagon concentrations were greater in the critically ill during fasting (p = 0.004) and after glucose infusion (p = 0.010) ( Table 2) .
GLP-1 and GIP. GLP-1 concentrations were greater in the critically ill during fasting (p = 0.004), but not after glucose infusion (p = 0.80), although the increment in GLP-1 did not differ significantly (p = 0.35) ( Table 2) . Fasting, glucose-stimulated, and incremental GIP concentrations were unaffected by critical illness (p = 0.35, p = 0.016, and p = 0.052, respectively) ( Table 2) .
Relationships Between Variables
Healthy subjects. Significant relationships were evident between transcript levels of SGLT-1 and GLUT2 at baseline in healthy subjects (ρ = 0.71; p = 0.009). There were, however, no other significant relationships between transcript levels, or between transcript levels and plasma levels of blood glucose, 3-OMG, GLP-1, or GIP in healthy subjects at any time point.
Critically ill patients. Relationships were evident between T1R2 copy number at baseline and blood glucose levels at baseline (ρ = 0.76; p = 0.004) and at 30 minutes (ρ = 0.77; p = 0.004). SGLT-1 copy number also related to fasting blood glucose levels in these patients (ρ = 0.58; p = 0.048). SGLT-1 Immunohistochemistry. Immunolabeling for T1R2 was evident in single cells dispersed throughout the duodenal epithelium in healthy subjects (Fig. 4) . These cells showed a homogenous distribution of label throughout the cytoplasm, were largely open or "flask" shaped, and found with equal frequency within villi or crypts. In dual labeling experiments, 19% ± 11% of T1R2 labeled cells coexpressed GLP-1, while 13% ± 8% of L-cells coexpressed T1R2 (Fig. 4A) . In a similar manner, 15% ± 10% of T1R2 labeled cells coexpressed GIP, while 12% ± 8% of K-cells coexpressed T1R2 (Fig. 4B) . SGLT-1 labeling was detected in the luminal membrane of duodenal epithelial cells, while GLUT2 was present in basolateral aspects of these cells in healthy subjects (Fig. 4, C and D) .
Mouse Model of Critical Illness
Sixteen of the 19 mice (84%) survived to day 5 following CLP surgery, while all 8 mice survived sham operation to day 5 (Fig.  5A) . CLP surgery was associated with significant morbidity, based on a cumulative disease index (p = 0.03) (Fig. 5B) . Jejunal Transcript Levels. As in humans, SGLT-1 was the most abundant transcript in mice, with 8.3-fold lower levels of GLUT2 (p < 0.001) (Fig. 1B) and much lower levels of T1R2 in sham mice (p < 0.001). Levels of SGLT-1 transcript were 55% lower in CLP mice compared to sham mice after 5 days (p < 0.001) (Fig. 2D) , while GLUT2 levels were halved (p = 0.002) (Fig. 2E) . T1R2 expression was 69% lower in CLP mice compared to sham mice (p = 0.004) (Fig. 2F) .
Glucose Absorption and Glycemia. (Fig. 3B) .
Relationships Between Variables
Sham-operated mice. There were no significant relationships between T1R2, SGLT-1, or GLUT 2 transcript levels and blood glucose or 3-OMG concentrations. Relationships were evident, however, between transcript levels of T1R2 and SGLT-1 (ρ = 0.70; p = 0.006), T1R2 and GLUT2 (ρ = 0.71; p = 0.006), and SGLT-1 and GLUT2 (ρ = 0.79; p < 0.001).
CLP mice. There were no relationships between transcript levels and 3-OMG concentrations, however, T1R2 levels at baseline negatively associated with blood glucose concentrations at baseline (ρ = -0.65; p = 0.043) and at 30 minutes (ρ = -0.66; p = 0.050). This was not seen for SGLT-1 or GLUT2. CLP mice showed a similar positive association between T1R2 and SGLT-1 levels (ρ = 0.51; p = 0.024), T1R2 and GLUT2 levels (ρ = 0.45; p = 0.048), and SGLT-1 and GLUT2 (ρ = 0.57; p = 0.009) as seen in sham mice.
DISCUSSION
This is the first study to evaluate potential molecular mechanisms underlying disordered nutrient absorption during critical illness. The primary observation is that critical illness is associated with markedly reduced intestinal levels of SGLT-1, GLUT2, and STR (T1R2) transcripts in both humans and a mouse model, providing a plausible explanation for the carbohydrate malabsorption observed during critical illness (4, 10, 20, 25) . The optimal amount of calories that should be administered as carbohydrate in mechanically ventilated critically ill patients remains uncertain. Studies evaluating the effect of energy delivery on clinical outcomes, including mortality, have yielded conflicting results (26, 27) . However, providing fewer calories may lead to significant late morbidity with poorer functional outcomes following hospital discharge (28, 29) , leading to speculation that provision of "full" feeding may protect against excessive catabolism and improve function in survivors (30) . However, increasing delivery of nutrients into the small intestine in excess of absorptive capacity is unlikely to be beneficial, and may be deleterious, if undigested carbohydrate passes into the large intestine leading to gas formation, abdominal distension, or diarrhea (20)-all of which are frequently observed in enterally fed critically ill patients (3). For these reasons, identification of the mechanisms underlying nutrient malabsorption, and the development of validated small animal models in which to study novel therapies directed at improving absorption, are likely to be important for improving outcomes in the critically ill.
The mechanisms underlying reduced SGLT-1 and GLUT2 expression in the critically ill are uncertain, but are likely to include diseaseinduced changes in cellular signaling within the intestinal epithelium (31) . In animals, it is established that the activation of intestinal STR has the capacity to regulate levels and function of SGLT-1, and in rats, the translocation of GLUT2 to the apical membrane (10, 12) . We observed a linear relationship between T1R2 expression and expression of both SGLT-1 and GLUT2 in mice in the current study, indicating that critical illness-induced reduction in intestinal STR may limit the ability of luminal glucose to upregulate SGLT-1 and GLUT2 effectively. Accordingly, the effect of novel therapies to stimulate STR, such as artificial sweeteners, could potentially increase the availability of SGLT-1 and GLUT2 transporters, and thereby enhance absorptive capacity, without exacerbating glycemic excursions. Such a hypothesis can now be evaluated in the CLP mouse model, with the potential to yield outcomes relevant to critically ill humans.
Our data support previous observations that not only is glucose absorption lower in the critically ill, but subsequent metabolism is disordered (4, 20) . Consistent with previous studies, increased glucagon with inadequate insulin secretion appeared important determinants of disordered glucose metabolism in this group (16, 17) . Given recent evidence of the essential role of SGLT-1 in incretin hormone release in rodents (32, 33) , we hypothesized that GLP-1 and GIP concentrations would be reduced in the critically ill when compared to health. In contrast, concentrations of these incretin hormones were at least maintained in patients, and fasting GLP-1 concentrations were increased. A possible explanation for the latter observation is that as a result of impaired nutrient absorption, undigested carbohydrate and lipid or excessive bile salts remain in the distal small intestine and colon even after an 8-hour fast, leading to continuing stimulation of GLP-1 secretion from L-cells in these regions (4, 34, 35) .
A particular strength of this study is that the same molecular and functional abnormalities that occurred within the small intestine of critically ill patients were observed in mice following CLP. In addition, the load and rate of glucose administered into the small intestine were controlled by direct intraduodenal infusion; this is important because the rate of nutrient delivery from the stomach into the small intestine is a major determinant of glucose absorption, glycemia, and the secretion of GLP-1 and GIP (36) , and gastric emptying is frequently known to be delayed in the critically ill (20, 37) . This study has several limitations. We did not quantify levels of SGLT-1, GLUT2, and T1R2 protein in human or mouse mucosa; however, given the marked difference in both transcript and 3-OMG absorption in both species, it is probable that protein levels would be affected similarly. Although we demonstrated linear relationships between T1R2 and SGLT-1 expression in mice that were standardized to receive a septic insult and resuscitation, these relationships were not apparent in humans, nor were linear relationships evident between SGLT-1 expression and 3-OMG concentrations in either species. However, the sample size was small and the critically ill patient cohort was a heterogeneous group studied at various times during their illness. Accordingly, the study is likely to be underpowered to detect relationships, particularly if such relationships are complex and nonlinear. There are other factors, such as flow of chyme within the intestinal lumen and mesenteric blood flow, which influence nutrient absorption, and may be adversely affected by critical illness (4, 9, 20, 38) . Although luminal and mesenteric blood flows may influence nutrient absorption, it is likely that transporter numbers are a pivotal determinant of glucose absorption in the critically ill. Given that the prolonged presence of an endoscope may be uncomfortable for some volunteers, we limited the duration of intraduodenal glucose infusion to 30 minutes. It would now be of interest to examine the effects of longer periods of glucose stimulation. Lastly, the patients studied were admitted due to a variety of injuries or illness. This may be relevant as it has been reported that traumatic brain injury stimulates GLUT2 but inhibits SGLT-1 in isolated rat jejunum (39) .
In conclusion, critical illness attenuates glucose absorption and markedly reduces the transcript numbers of glucose transporters and STRs in the small intestinal mucosa.
